NORTH BRISTOL NATIONAL HEALTH SERVICE TRUST

Their core work

North Bristol NHS Trust is a major UK hospital trust based in Bristol that delivers acute healthcare services while actively engaging in clinical research. Their H2020 involvement spans clinical trials for new antibiotics, diabetes prevention programmes, kidney disease management, and robotic surgery — reflecting a hospital that translates bedside observations into research contributions. They bring real patient populations, clinical infrastructure, and frontline medical expertise to European research consortia, particularly in infectious disease, metabolic disorders, and renal medicine.

What they specialise in

How they've shifted over time

Their earliest H2020 involvement (2017) started with digital surgical technology (SMARTsurg), then shifted firmly into clinical medicine — kidney disease management (IMPROVE-PD, 2019) and antimicrobial resistance (GNA NOW, 2019). By 2020, their focus had moved towards public health prevention, with IMPACT DIABETES B2B addressing gestational diabetes through mHealth and behaviour change. The trajectory shows a clear move from technology-assisted surgery toward large-scale clinical trials and preventive health programmes.

NBT is moving toward population-level health challenges — antimicrobial resistance and metabolic disease prevention — where their clinical trial infrastructure and patient access are most valuable.

How they like to work

NBT operates exclusively as a participant or third party — they have never coordinated an H2020 project, which is typical for NHS trusts that contribute clinical sites and patient cohorts rather than leading research design. With 49 unique partners across 14 countries, they plug into large, well-funded consortia where their role is providing clinical validation, patient recruitment, and real-world healthcare data. They are a reliable clinical partner rather than a project driver.

NBT has collaborated with 49 distinct partners across 14 countries, indicating broad European reach through large multi-site clinical consortia. Their network is built through participation in major health research projects rather than through repeated partnerships with a core group.

What sets them apart

As an NHS hospital trust, NBT offers something universities and research institutes cannot: direct access to diverse patient populations within a functioning national health system. Their strength lies in running clinical trial sites, recruiting patients, and providing real-world clinical data from routine care. For any consortium needing a UK clinical partner with experience in infectious disease trials, renal medicine, or diabetes prevention, NBT brings both the infrastructure and the regulatory experience of operating within the NHS.

Highlights from their portfolio

• GNA NOW
  By far their largest project (EUR 2.35M), addressing the global AMR crisis by developing new gram-negative antibiotics through clinical trials — a high-priority public health area.
• IMPACT DIABETES B2B
  Combines mHealth technology with behaviour change science to prevent diabetes from pregnancy onward — represents their move into digital preventive health.
• IMPROVE-PD
  Tackles personalised medicine for peritoneal dialysis patients using disease registries and experimental models, bridging clinical care with data-driven research.